Zydus Lifesciences gets USFDA’s final approval for Sugammadex Injection

06 Oct 2023 Evaluate

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL), Single-Dose Vial (USRLD: Bridion Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL)).

Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. The injection will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara, India.

Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL), Single-Dose Vial had annual sales of $986 million in the United States (IQVIA MAT August 2023). The group now has 381 approvals and has so far filed over 444 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.


Zydus Lifesciences Share Price

875.05 -6.05 (-0.69%)
20-Jan-2026 12:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1639.70
Dr. Reddys Lab 1184.30
Cipla 1378.30
Zydus Lifesciences 875.05
Lupin 2163.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×